All In Biotech

Drug Trial Radar · NCT07897227

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of SYS6062 in Patients With Advanced Solid Tumors.

A Phase I/II Study of Dose Escalation, PK Expansion, and Cohort Expansion to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of SYS6062 in Patients With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

260

Planned (sponsor's estimate)

Start

Nov 1, 2026

Primary completion

May 1, 2029

Study completion Nov 1, 2029

Sponsor

Sponsor type
Industry
First posted
Oct 27, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a multicenter, open-label, dose-escalation, PK expansion, and cohort expansion, first-in-human phase I/II study to evaluate the safety, tolerability, PK profile, and preliminary antitumor efficacy of SYS6062, a CEACAM5-targeted antibody-conjugate drug, in patients with advanced solid tumors.

Conditions

  • Advanced Solid Tumors
  • Gastric Cancer (GC)
  • Colorectal Cancer (CRC)
  • Pancreatic Ductal Adenocarcinoma (PDAC)

Interventions

  • SYS6062Biological

    Intravenous infusion will be administered until disease progression or intolerable toxicity

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse events (AEs) and serious adverse events (SAEs)Time frame: Up to 3 years
  2. Dose-limiting toxicities (DLTs)Time frame: Up to approximately 1 year
  3. Maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D)Time frame: Up to approximately 1 year

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.